GlassScriptPhysician profile
Sharma S Prabhakar
NPI 1508855883
$5,191.28
in general payments reported to CMS, 2019-2025
22 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $33.81 · 2021: $188 · 2022: $2,730 · 2023: $83.80 · 2024: $718 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.80 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $2,313.96 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $553.37 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $335.31 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $266.57 | 2019-2024 | Farxiga |
| Akebia Therapeutics INC | $259.46 | 2025 | Vafseo, Auryxia |
| Amgen INC. | $158.60 | 2024-2025 | Tavneos, Krystexxa |
| Regeneron Healthcare Solutions, INC. | $145.59 | 2022 | |
| Aurinia Pharma U.S., INC. | $136.35 | 2025 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $134.53 | 2023-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $133.56 | 2025 | |
| Horizon Therapeutics Plc | $126.34 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $124.23 | 2024-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $119.54 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $100.23 | 2025 | Acthar |
| Travere Therapeutics, INC. | $80.89 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $44.54 | 2025 | Defencath |
| Baxter Healthcare | $37.58 | 2020-2022 | |
| Nxstage Medical, INC. | $33.93 | 2025 | Nxstage System One |
| Ardelyx, INC. | $32.15 | 2025 | Xphozah 30 Mg |
| Allergan, INC. | $23.93 | 2019 | |
| Pfizer INC. | $15.33 | 2019 | |
| Abbvie INC. | $15.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharma Prabhakar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.